Literature DB >> 16579254

Red blood cell transfusions in patients undergoing lower extremity artery bypass surgery.

T T Niemi1, A H Kuitunen, J Haukka, M Lepäntalo.   

Abstract

BACKGROUND AND AIMS: The purpose of this study was to search predictors of red blood cell transfusions in peripheral vascular surgical patients.
MATERIAL AND METHODS: All the patients who undergone infrainguinal bypass surgery at Helsinki University Hospital in the year 2000 were included. Of 266 records 261 (98%) were available for data review. Multiple stepwise regression model was created to identify independent predictors of blood use. RESULTS AND
CONCLUSIONS: 174 (67%) of the patients received red blood cell transfusion. The lowest measured mean (SD) haemoglobin was 94 (11) g/l intraoperatively and 92 (+/- 10) g/l on the first two postoperative days. The median (range) number of units was 3 (1-19). Multivariate analysis showed that high age (p = 0.019), small body surface area (p = 0.017), low preoperative haemoglobin (p < 0.001), blood loss (p < 0.001), long lasting surgery (p<0.001), reoperation (p=0.018), femoro-distal reconstruction (p=0.048) and chronic obstructive pulmonary disease (p = 0.023) increased the risk to receive red blood cell transfusion. The frequent use of antithrombotic medication (72% of the patients) did not significantly increase red blood cell administration. The generous use of red blood cells despite relative safe haemoglobin levels indicates a need for a standardized multidisciplinary transfusion strategy in this patient population. Otherwise, most of the predictors for red blood cell administration were nonmodifiable.

Entities:  

Mesh:

Year:  2006        PMID: 16579254     DOI: 10.1177/145749690609500108

Source DB:  PubMed          Journal:  Scand J Surg        ISSN: 1457-4969            Impact factor:   2.360


  1 in total

1.  Monitoring compliance with transfusion guidelines in hospital departments by electronic data capture.

Authors:  Astrid Norgaard; Trine Honnens De Lichtenberg; Jens Nielsen; Pär I Johansson
Journal:  Blood Transfus       Date:  2014-06-05       Impact factor: 3.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.